Renalytix AI (GB:RENX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Renalytix AI, an AI-enabled diagnostics firm specializing in kidney disease, reported a total revenue of $2.3 million for FY24, with losses before tax totaling $44.9 million due to significant impairment and fair value adjustments. The company’s total assets stood at $7.3 million, including $4.7 million in cash, by the end of June 2024. Investors are anticipated to see differences between US GAAP and IFRS audited results, specifically in the treatment of intangibles.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
